310 related articles for article (PubMed ID: 16305990)
1. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
2. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
3. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Suppiah R; Srkalovic JG; Hussein MA
Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
6. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
10. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Kalmadi S; Baz R; Mahindra A
Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC
Leukemia; 2003 Jan; 17(1):41-4. PubMed ID: 12529658
[TBL] [Abstract][Full Text] [Related]
13. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
14. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Sekeres MA; List A
Curr Hematol Rep; 2005 May; 4(3):182-5. PubMed ID: 15865869
[TBL] [Abstract][Full Text] [Related]
16. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Bartlett JB; Tozer A; Stirling D; Zeldis JB
Br J Cancer; 2005 Sep; 93(6):613-9. PubMed ID: 16222306
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
18. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
19. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
